Thromboinflammatory Biomarkers of Cardiorenal Syndrome in Patients With End-Stage Renal Disease

Clinical and Applied Thrombosis/Hemostasis, Journal Year: 2024, Volume and Issue: 30

Published: Jan. 1, 2024

Cardiovascular disease is a prevalent complication in patients with end-stage renal (ESRD) on maintenance hemodialysis. In the ESRD patient population, cardiovascular mortality 20 times higher compared to general population. The strong relationship between both illnesses can be explained through cardiorenal syndrome (CRS). CRS encompasses spectrum of disorders involving heart and kidneys which acute or chronic dysfunction one organ may induce similar effect other organ. Current literature reveals that inflammation thrombosis are integral development. Hence, this study aims demonstrate whether thromboinflammatory biomarkers laboratory parameters correlate progression development CRS. Ninety-five were recruited at Loyola University Medical Center hemodialysis unit. Epic chart analysis was used determine Biomarkers (C-reactive protein, tumor necrosis factor alpha, interleukin-6, Annexin V, L-fatty acid binding monocyte chemoattractant protein 1, nitric oxide, von Willebrand factor, D-dimer, plasminogen activator inhibitor-1) profiled using enzyme-linked immunosorbent assay method without cohort. All significantly elevated normal controls ( P < .05) parameters, ferritin (521.99 ± 289.33) PTH (442.91 1.50). Through EPIC 47% have D-dimer TNF-α This suggests biomarkers, TNF-α, good predictors patients.

Language: Английский

---

Blood Volume Analysis and Cardio-renal syndrome: from bench to bedside

Cardiorenal Medicine, Journal Year: 2024, Volume and Issue: 14(1), P. 483 - 497

Published: July 20, 2024

Background: This review delves into the intricate landscape of cardiorenal syndrome (CRS) and highlights pivotal role blood volume analysis (BVA) in improving patient care outcomes. Summary: BVA offers a direct highly accurate quantification intravascular volume, red cell plasma complete with patient-specific norms. diagnostic tool enhances precision diuretic therapies, significantly elevating effectiveness conventional care. Key Messages: Our objectives encompass comprehensive understanding how informs evaluation treatment CRS, including its subtypes, pathophysiology, clinical significance. We delve principles, techniques, measurements, elucidating potential advantages compared to commonly used surrogate measures. dissect relevance various CRS scenarios, emphasizing unique contributions each subtype. By assessing tangible impact on outcomes through meticulous relevant studies, we unveil enhance health optimize resource utilization. Acknowledging challenges limitations associated BVA’s implementation, underscore importance multidisciplinary collaboration among cardiologists, nephrologists, other clinicians. Finally, identify research gaps propose future directions for contributing ongoing advancements this field patients affected by complicated syndrome.

Language: Английский

---

A Systematic Review of Uremic Toxin Concentrations and Cardiovascular Risk Markers in Pediatric Chronic Kidney Disease

Toxins, Journal Year: 2024, Volume and Issue: 16(8), P. 345 - 345

Published: Aug. 8, 2024

Chronic kidney disease (CKD) can lead to cardiac dysfunction in a condition known as cardiorenal syndrome (CRS). It is postulated that the accumulation of uremic toxins bloodstream, consequence declining function, may contribute these adverse effects. While CRS adults has been extensively studied, there significant knowledge gap with pediatric patients. Uremic toxin levels children remain inadequately characterized and quantified compared adults. This review aims systematically evaluate association between concentrations changes examine impact different dialysis modalities, specifically hemodialysis peritoneal dialysis, on clearance cardiovascular parameters. To address this, we conducted systematic literature search PubMed, following PRISMA guidelines. We used terms "uremic toxins" "cardiorenal syndrome" variations syntax for studies discussing relationship CKD, subsequent parameters, emergence dysfunction. Full-text articles written English, humans aged from birth 18 years, published until December 2021 were included. A comprehensive yielded six studies, their risk bias was assessed using JBI Critical Appraisal Checklists. Our registered PROSPERO, number CRD42023460072. synthesis intends provide an understanding role CRS. The findings reveal patients end-stage CKD exhibit elevated levels, which are significantly associated Additionally, severity correlated higher levels. No conclusive evidence found support superiority either or outcomes. More pediatric-specific standardized longitudinal needed develop targeted treatments improve clinical outcomes quality life affected children.

Language: Английский

---

Effects of WN1703 on Cardiovascular Function in Chronic Hyperuricemia Rats and Myocardial Injury Mechanism Exploration in H9C2 Cells

Journal of Applied Toxicology, Journal Year: 2024, Volume and Issue: unknown

Published: Oct. 22, 2024

ABSTRACT Hyperuricemia, a prevalent condition, is typically preceded by disturbances in purine metabolism and frequently associated with hyperlipidemia other dysfunctions of metabolism. WN1703 demonstrated an inhibitory activity against xanthine oxidoreductase (XOR) that was comparable to febuxostat our prior investigation. In this study, we assessed the cardiovascular safety chronic hyperuricemia rat model induced potassium oxonate combination hypoxanthine. We investigated changes biomarkers rats treated WN1703, including creatine kinase (CK), CK‐MB, B type natriuretic peptide (BNP), Corin protein (CRN), Neprilysin (NEP), myeloperoxidase (MPO), 8‐hydroxy‐2‐deoxyguanosine (8‐OHdG), tumor necrosis factor (TNF‐α), interleukin‐1β (IL‐1β), interleukin‐8 (IL‐8). Additionally, validated potential mechanism cardiac injury H9C2 cells, guided cardiotoxicity predictions from cardioToxCSM database network pharmacology. observed excessively rapid urate‐lowering, oxidative stress, inflammation could disrupt myocardial functional homeostasis increase risk rats, treatment effectively reduced levels stress marker 8‐OHdG inflammatory TNF‐α. Despite absence organic damage heart prolonged hazard be modulation TGFβ RHO/ROCK signaling pathways WN1703. This offer new insights into mechanisms underlying adverse effects caused XOR inhibitors.

Language: Английский

---

NAD+ enhancers as therapeutic agents in the cardiorenal axis

Cell Communication and Signaling, Journal Year: 2024, Volume and Issue: 22(1)

Published: Nov. 8, 2024

Cardiorenal diseases represent a complex interplay between heart failure and renal dysfunction, being clinically classified as cardiorenal syndromes (CRS). Recently, the contributions of altered nicotinamide adenine dinucleotide (NAD

Language: Английский

---